Active substance
Results for the substance tozinameran/riltozinameran covid-19 mrna vaccine (with modified nucleosides)
1 result
About this active substance
Tozinameran-riltozinameran is an mRNA-based vaccine used for the prevention of SARS-CoV-2 infection, the causative agent of COVID-19. It contains mRNA encoding the viral spike protein, encapsulated in a lipid nanoparticle to facilitate cellular delivery.
The vaccine works by stimulating the immune system to produce antibodies and activate T-cells against the spike protein, providing protection against infection and severe disease. It is administered intramuscularly, typically in two doses several weeks apart.
Common side effects include pain at the injection site, fatigue, headache, fever, and chills. In rare cases, severe adverse reactions such as myocarditis, pericarditis, or allergic reactions may occur. Post-vaccination monitoring is essential to promptly identify and manage these reactions.
Tozinameran-riltozinameran represents an innovative technology in COVID-19 prevention, significantly contributing to reducing virus transmission and protecting public health.
The vaccine works by stimulating the immune system to produce antibodies and activate T-cells against the spike protein, providing protection against infection and severe disease. It is administered intramuscularly, typically in two doses several weeks apart.
Common side effects include pain at the injection site, fatigue, headache, fever, and chills. In rare cases, severe adverse reactions such as myocarditis, pericarditis, or allergic reactions may occur. Post-vaccination monitoring is essential to promptly identify and manage these reactions.
Tozinameran-riltozinameran represents an innovative technology in COVID-19 prevention, significantly contributing to reducing virus transmission and protecting public health.